After Merrill Lynch and Barclays gave Alector Inc (NASDAQ: ALEC) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Yaron Werber maintained a Buy rating on Alector Inc today. The company’s shares opened today at $18.52.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 16.4% and a 69.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Unum Therapeutics Inc, and Acceleron Pharma.
Alector Inc has an analyst consensus of Strong Buy, with a price target consensus of $26.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.84 and a one-year low of $15.16. Currently, Alector Inc has an average volume of 562K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALEC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.
